New adaptive therapy aims to outsmart prostate cancer
NCT ID NCT03511196
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests an adaptive approach to hormone therapy for men with stage IV prostate cancer that still responds to hormone treatment. Instead of a fixed schedule, the treatment is adjusted based on PSA levels. The study includes 17 participants and combines standard drugs (abiraterone and prednisone) with a GnRH agonist. The main goal is to see if men can stay on the study for at least a year without their cancer worsening.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Androgen deprivation therapy (ADT) with leuprolide, goserelin, or triptorelin, plus abiraterone and prednisone
- What this could lead to
- If successful, this could point toward a personalized treatment schedule that delays cancer progression while reducing side effects for men with advanced prostate cancer.
- What could go wrong
- This is a very early phase 1b trial with only 17 participants, so results may not apply to all patients. The adaptive approach may not improve outcomes or could lead to faster progression in some cases.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA OF THE PROSTATE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- Can a new injection tame prostate cancer by cutting testosterone?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks